ex·clu·sivi·ty (n.) – period of uniqueness, typically accompanied by envy and profit
Executive Summary
FDA recognizes data and market exclusivity in its drug approval process, which emanated from laws encouraging the development of drugs for rare diseases and allowing for generic drugs, although the terms themselves do not appear in the bills.
You may also be interested in...
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Rising concerns among generic firms about how FDA will interpret biosimilar exclusivity provisions may have escalated due to fears about the consequences of increased congressional scrutiny of the new pathway.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.